Complete regression of generalized plasmacytoma of lymph nodes in a liver transplant recipient during the conversion of immunosuppressive therapy from tacrolimus to everolimus ; Полная регрессия генерализованной плазмоцитомы лимфатических узлов у реципиента трансплантата печени на фоне конверсии иммуносупрессивной терапии с такролимуса на эверолимус

Authors: V. E. Syutkin, V. R. Gorodetskiy, A. A. Salienko, N. A. Probatova, N. A. Kupryshina, M. S. Novruzbekov, В. Е. Сюткин, В. Р. Городецкий, А. А. Салиенко, Н. А. Пробатова, Н. А. Купрышина, М. С. Новрузбеков

Source: Transplantologiya. The Russian Journal of Transplantation; Том 13, № 3 (2021); 272-279 ; Трансплантология; Том 13, № 3 (2021); 272-279 ; 2542-0909 ; 2074-0506 ; 10.23873/2074-0506-2021-13-3

Subject Terms: эверолимус, post-transplant lymphoproliferative diseases, proliferation signal inhibitors, everolimus, посттрансплантационные лимфопролиферативные заболевания, ингибиторы пролиферативного сигнала

File Description: application/pdf

Relation: https://www.jtransplantologiya.ru/jour/article/view/587/638; https://www.jtransplantologiya.ru/jour/article/view/587/644; Doak PB, Montgomerie JZ, North JD, Smith F. Reticulum cell sarcoma after renal homotransplantation and azathioprine and prednisone therapy. Br Med J. 1968;4(5633):746–748. PMID: 4881420 https://doi.org/10.1136/bmj.4.5633.746; Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984;1(8377):583–587. PMID: 6142304 https://doi.org/10.1016/s0140-6736(84)90994-2; Swerdlow S. Post-transplant lymphoproliferative disorders. In: WHO classification of tumours of haematopoietic and lymphoid tissues. 4 th ed. Lyon: International Agency for Research on Cancer; 2017. p. 453–462.; Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol. 2005;56(1):155–167. PMID: 15979320 https://doi.org/10.1016/j.critrevonc.2005.03.015; Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol. 2004;124(6):717–726. PMID: 15009059 https://doi.org/10.1111/j.1365-2141.2004.04834.x; Kilciksiz S, Karakoyun-Celik O, Agaoglu FY, Haydaroglu A. A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. Sci World J. 2012;2012:895765. PMID: 22654647 https://doi.org/10.1100/2012/895765; Trappe R, Zimmermann H, Fink S, Reinke P, Dreyling M, Pascher A, et al. Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell posttransplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases. Haematologica. 2011;96(7):1067–1071. PMID: 21719885 https://doi.org/10.3324/haematol.2010.039214; Richendollar BG, Hsi ED, Cook JR. Extramedullary plasmacytoma-like posttransplantation lymphoproliferative disorders: clinical and pathologic features. Am J Clin Pathol. 2009;132(4):581– 588. PMID: 19762536 https://doi.org/10.1309/AJCPX70TIHETNBRL; Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8(3):173–183. PMID: 23737188 https://doi.org/10.1007/s11899-013-0162-5; El-Salem M, Raghunath PN, Marzec M, Wlodarski P, Tsai D, Hsi E, et al. Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders. Lab Invest. 2007;87(1):29–39. PMID: 17075574 https://doi.org/10.1038/labinvest.3700494; Nepomuceno RR, Balatoni CE, Natkunam Y, Snow AL, Krams SM, Martinez OM. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res. 2003;63(15):4472–4480. PMID: 12907620; Majewski M, Korecka M, Kossev P, Li S, Goldman J, Moore J, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA. 2000;97(8): 4285–4290. PMID: 10759564 https://doi.org/10.1073/pnas.080068597; Majewski M, Korecka M, Joergensen J, Fields L, Kossev P, Schuler W, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation. 2003;75(10):1710–1717. PMID: 12777861 https://doi.org/10.1097/01.TP.0000063934.89714.19; Cullis B, D'Souza R, McCullagh P, Harries S, Nicholls A, Lee R, et al. Sirolimus- induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis. 2006;47(5):e67–72. PMID: 16632009 https://doi.org/10.1053/j.ajkd.2006.01.029; Boratynska M, Smolska D. Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders. Transpl Int. 2008;21(6):605– 608. PMID: 18282244 https://doi.org/10.1111/j.1432-2277.2008.00655.x; Pascual J. Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors. Nephrol Dial Transplant. 2007;22(Suppl 1): i27–35. PMID: 17456616 https://doi.org/10.1093/ndt/gfm088; Nanmoku K, Shinzato T, Kubo T, Shimizu T, Yagisawa T. Remission of Epstein-Barr virus-positive post-transplant lymphoproliferative disorder by conversion to everolimus in a kidney transplant recipient. Transpl Infect Dis. 2019;21(4):e13116. PMID: 31102475 https://doi.org/10.1111/tid.13116; Li J, Liu Z, Li Y, Jing Q, Wang H, Liu H, et al. Everolimus shows synergistic antimyeloma effects with bortezomib via the AKT/mTOR pathway. J Investig Med. 2019;67(1):39–47. PMID: 29997148 https://doi.org/10.1136/jim-2018-000780; Günther A, Baumann P, Burger R, Kellner C, Klapper W, Schmidmaier R, et al. Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study. Haematologica. 2015;100(4):541–547. PMID: 25682600 https://doi.org/10.3324/haematol.2014.116269; Brennan DC, Aguado JM, Potena L, Jardine AG, Legendre C, Säemann MD, et al. Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms. Rev Med Virol. 2013;23(2):97–125. PMID: 23165654 https://doi.org/10.1002/rmv.1733; Pascual J, Royuela A, Fernández AM, Herrero I, Delgado JF, Solé A, et al. Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients. Transpl Infect Dis. 2016;18(6):819–831. PMID: 27600985 https://doi.org/10.1111/tid.12601; https://www.jtransplantologiya.ru/jour/article/view/587

Availability: https://www.jtransplantologiya.ru/jour/article/view/587
https://doi.org/10.23873/2074-0506-2021-13-3-272-279